ADIA · Adia Nutrition, Inc.
$0.13
-0.01 (-7.59%)
At close · Aug 31
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern for one year after the audit report is dependent upon, among other things, its ability to generate greater revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts.”View the 10-Q filed Aug 13, 2026
Market Cap
$13.69M
Shares
94.40M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$700.51K
+10879.7%
FY2025
Net Income
-$395.46K
-118.4%
FY2025
Gross Margin
27.36%
-7pp
FY2025
Operating Margin
-52.32%
+2686.7pp
FY2025
Diluted EPS
$0.00
FY2025
Operating Cash Flow
-$179.23K
+46.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 |
|---|---|---|
| $700.51K | $6380 | |
| $508.84K | $4186 | |
| $191.67K | $2194 | |
| 27.36% | 34.39% | |
| $29.14K | $0 | |
| $479.96K | $140.41K | |
| $4142 | $433 | |
| $558.16K | $176.94K | |
| -$366.49K | -$174.75K | |
| -52.32% | -2739.01% | |
| -$362.35K | -$174.32K | |
| $31.6K | $6318 | |
| -$28.97K | -$6318 | |
| -$395.46K | -$181.07K | |
| $0 | $0 | |
| -$395.46K | -$181.07K | |
| -56.45% | -2838.04% | |
| USD/shares | $0.00 | $0.00 |
| USD/shares | $0.00 | $0.00 |
| shares | 93.6M | 91.74M |
| shares | 93.6M | 91.74M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Adia Labs | $448,888 | $0 |
| AdiaMed | $245,960 | $0 |
| Biolete | $3,393 | $6,380 |
| Corporate | $2,267 | $0 |
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Sales of Prducts and Services | $700,508 | $6,380 |
| Sales of Biologics | $443,750 | $0 |
| Biologics | $289,588 | $0 |
| Medical Procedures | $245,600 | $0 |
| Procedures | $217,955 | $0 |
| Shipping and Delivery | $5,138 | $0 |
| Sales of Supplements | $3,393 | $6,380 |
| Services | $2,267 | $0 |
| Supplements | $1,295 | $4,186 |
| Sales of Ancillary Products | $360 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Adia Labs | $148,783 | -$1,947 |
| Biolete | -$247 | -$25,839 |
| AdiaMed | -$198,889 | -$21,367 |
| Corporate | -$316,139 | -$125,596 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 |
|---|---|---|
| Adia Labs | 33.1% | — |
| AdiaMed | -80.9% | — |
| Biolete | -7.3% | -405% |
| Corporate | -13945.3% | — |